Janssen Search
Search results
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
Sep 10, 2024 United States Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ®, a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO, CA, September 10, ...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
Sep 14, 2024 Spain Post-progression outcomes showed significant and sustained improvement for RYBREVANT ® plus standard of care versus chemotherapy alone BARCELONA, September 14, 2024 – Johnson & Johnson (NYSE:JNJ) today announced updated results from ...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
Aug 20, 2024 United States RYBREVANT ® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT ...
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
Sep 19, 2024 United States Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT ® this year, with four indications overall RARITAN, New Jersey (September 19, 2024) – Johnson ...
CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
Jun 28, 2024 Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers 1 The CHMP’s recommendation is based on results from Cohort 1 of ...
Phase 3 MARIPOSA-2 Study Shows RYBREVANT (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56% and 52% in Patients with EGFR-Mutated NSCLC who Progressed on or after Osimertinib
Oct 23, 2023 Spain Phase 3 MARIPOSA-2 Study Shows RYBREVANT ® (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56 and 52 Percent Respectively in Patients with EGFR-Mutated Non-Small Cell ...
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
May 18, 2023 United States Launch of Multidisciplinary Council of Experts Call-to-Action During EHA Demonstrates Continued Commitment to Innovation in Multiple Myeloma RARITAN, N.J., May 18, 2023 — The Janssen Pharmaceutical Companies of Johnson & ...
Johnson & Johnson advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA
May 23, 2024 PALOMA-3 presentation of subcutaneous amivantamab and lazertinib selected to showcase cutting-edge approaches in lung cancer during prestigious "Best of ASCO" program New data showcase first- and-best-in-class, complementary ...